Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
07 Juin 2019 - 7:01AM
Communication from the Board of Directors
Paul Hudson to succeed Olivier Brandicourt as Chief Executive
Officer
PARIS - June 7, 2019 - At its meeting on
June 6th of 2019, Sanofi's Board of Directors unanimously appointed
Paul Hudson as Chief Executive Officer of the Group, to succeed
Olivier Brandicourt who has decided to retire.
The Board of Directors would like to thank
Olivier Brandicourt for the energy with which he has steered the
Group through a complex period and for his decisive contribution to
the company's return to growth. Thanks to the actions undertaken
during his term of office, Sanofi is able to accelerate its growth,
and has powerful assets to regain the position it needs to
occupy.
As of September 1, 2019, he will be replaced by
Paul Hudson, who most recently was Chief Executive Officer of
Novartis Pharmaceuticals and Member of the Executive Committee of
Novartis.
Paul Hudson, 51 years old, is a seasoned leader
with a strong international experience, particularly in the United
States, Japan and Europe. He spent his 28-years career with major
pharmaceutical companies such as Schering Plough, Astra Zeneca and
Novartis. Throughout his various management positions, he has
proven his strategic vision, his strong leadership and his ability
to achieve the greatest challenges, particularly in terms of
innovation and digital transformation. Mr. Hudson has a very robust
track record in successful major product launches. Paul Hudson will
move to Paris.
Serge Weinberg, Chairman of the Board of
Directors of Sanofi, said: "We are very pleased that Paul Hudson
has agreed to join Sanofi. His skills and experience give him all
the assets he needs to accelerate growth and lead the Group's
adaptation to new strategic challenges, particularly in the areas
of Research and Development and digital. His human values will
enable him to mobilize all the energies and increase the agility,
that a group such as Sanofi needs, to face the new challenges of
our industry and the changes in healthcare systems around the
world".
About Sanofi Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Head of Communication,
SanofiJosep Catlla Tél.: +33 (0) 7 89 07 80 33
Josep.catlla@sanofi.com |
Image7Anne MéauxTél.: +33
(0) 6 89 87 61 76ameaux@image7.fr
Image7Laurence Heilbronn Tél.: +33 (0) 6 89 87 61
37lheilbronn@image7.fr |
|
About Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024